Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We aimed to evaluate the genomic ETV6-RUNX1 fusion sites as a single marker for MRD quantification.
|
31034759 |
2019 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017).
|
31364309 |
2019 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Clinical and biological disease characteristics did not differ between the two subgroups of adolescents, including minimal residual disease (MRD) results during initial therapy, except for ETV6-RUNX1 frequency and gender.
|
31629941 |
2019 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Group A showed higher incidence of lymphadenopathy and TEL-AML1 fusion gene than group B. CD304 was reevaluated in group A patients at day 28 postinduction chemotherapy which revealed 12/28 (42.9%) patients with persistent CD304 expression (MRD; group A1) and 16/28 (57.1%) patients who turned CD304 (MRD; group A2).
|
29200164 |
2018 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MRD-positive status was defined as a <4.5-log reduction from diagnosis in <i>RUNX1-RUNX1T1</i> transcripts and/or the loss of a ≥4.5-log reduction after 3 months after HSCT.
|
30076280 |
2018 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we determined whether RT-qPCR of the ETV6-RUNX1 fusion transcript can be a reliable alternative for MRD analysis.
|
28004528 |
2017 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Patients with t(12;21)/(ETV6-RUNX1) or hyperdiploidy >50 ALL had the best prognosis; those with a negative MRD on day 19 had a particularly low risk of relapse: 1.9% and 3.8%, respectively.
|
27560110 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We identified that poor-risk karyotype showed very poor outcome after auto-HCT, and then analyzed 85 patients with good to intermediate-risk molecular cytogenetics with available molecular study results and markers for minimal residual disease (MRD) such as WT1 and core-binding factor (CBF) associated MRD (ie, AML1/ETO and CBFβ/MYH11).
|
28089879 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The identification of the genomic sequence of the breakpoint flanking regions of the ETV6-RUNX1 translocation should be the best strategy to monitor minimal residual disease (MRD) in patients with ETV6-RUNX1-positive ALL.
|
26711002 |
2016 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations.
|
25082877 |
2014 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
RUNX1-RUNX1T1 fusion transcript is a well-established marker for minimal residual disease (MRD) monitoring.
|
24616160 |
2014 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Both RT-PCR and RQ-PCR can be used to detect MRD in childhood AML1/ETO AML.
|
24920269 |
2014 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MRD status was the strongest predictor of outcome with 5 year EFS rates greater that 90% seen in those patients with low-risk MRD and this was associated with TEL/AML1 rearrangement, high hyperdiploidy (HH) karyotype and female gender.
|
23242576 |
2013 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels.
|
23535063 |
2013 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The fusion gene AML1/ETO is a molecular marker for monitoring minimal residual disease (MRD) in acute myeloid leukemia with the t(8;21)(q22;q22) translocation.
|
23613269 |
2013 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g.AML1-ETO, CBFB-MYH11, MLL, FLT-3).
|
22196957 |
2012 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
ETV6-RUNX1 was associated with age 1-9 years, pre-treatment classification as low risk and lower levels of minimal residual disease (MRD) on day 19 of therapy (P<0.001).
|
21869842 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In core binding factor (CBF) acute myeloid leukaemia (AML), realtime quantitative PCR is useful to quantify the fusion transcript ratio (CBFβ-MYH11 and AML1-ETO, in case of inv(16) and t(8;21) respectively) in peripheral blood and bone marrow during the courses of chemotherapy, in order to monitor minimal residual disease (MRD).
|
22871474 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Patients with TEL-AML1 and E2A-PBX1 fusion genes or other B cell precursor ALLs (BCP-ALL) had favorable clinical features, were sensitive to prednisone, had low minimal residual disease (MRD), and an excellent prognosis, with a 5-year event-free survival (EFS) of 84-92%.
|
22911440 |
2012 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To examine the prognostic significance of minimal residual disease (MRD) in t(8;21) acute myeloid leukemia (AML), 96 bone marrow samples from 26 Japanese patients in complete remission (CR) were analyzed regarding the RUNX1/MTG8 transcript using real-time reverse transcriptase polymerase chain reaction assay.
|
18553224 |
2008 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
So, persistence of TEL-AML1 fusion as a MRD had no additive prognostic value over its measurement at diagnosis in terms of predicting the probability of OS.
|
18928518 |
2008 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
After adjusting for known prognostic features such as presence of the TEL-AML1 rearrangement, National Cancer Institute (NCI) risk status, ploidy, and race, the G allele of a common polymorphism in chemokine receptor 5 (CCR5) was associated with more favorable MRD status than the A allele (P = .009, logistic regression), when comparing "best" and "worst" risk groups.
|
18182569 |
2008 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Institute high-risk (NCI HR) patients who were MRD(+).
|
18388178 |
2008 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Blotting analysis of the levels of the TEL-AML1 fusion transcript was used to detect minimal residual disease.
|
18635414 |
2008 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
|
12764380 |
2003 |